Johnson & Johnson wins EU approval to buy Actelion
The European Commission’s Directorate-General for Competition has conditionally cleared pharmaceutical company Johnson & Johnson’s acquisition of Swiss biotechnology company Actelion after a Phase I review, subject to conditions aimed at maintaining competition in the development of insomnia drugs.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.